“Tell them is fake news, work of moose and squirrel.”
ADHD QUIZ!!!!

The average genetic contribution to ADHD is:
80%, 60%, 40%, or 20%

If your child is ADHD, the probability you have it is:
70%, 50%, or 20%

The first accurate description of the ADHD syndrome was in: 1798, 1842, 1913, 1974

In any given patient, all stimulants (dextroamphetamine or ritalin) are all about equally effective: true or false?

Who refills their ADHD med prescriptions the least? Kids, adolescents, college kids, or elderly?

Psychostimulants help non-ADHD individuals drive better? True or false?

It is proven that psychostimulants are effective boosters to antidepressants. True or false?
Fidgety Phil (Heinrich Hoffmann 1809–1894)
The questions clinicians want answered:

• How do I diagnose adult ADHD in the outpatient setting?
  – Highest specificity in particular
  – Malingering?

• How do I decide on which stimulant or non-stimulant to use and at what doses?

• How to deal with co-morbid substance use?

• How do I deal with the comorbidity as regards:
  – What do I treat first?
  – Contraindications to stimulant use?
ADHD: An Enormously Common and Impairing Disorder

Prevalence 18- to 44-year-olds: 4.4%
Percentage of adults with ADHD who received treatment within the previous 12 months: 11%

High degree of psychiatric comorbidities, eg, major depression, anxiety disorders, bipolar disorder, SUD, etc

Impairment in multiple domains (home, social, school, work)

Chronic course
~75% persistence from childhood into adolescence
~50% persistence from childhood into adulthood

SUD = substance use disorder.
**DSM-5 Criteria for ADHD:**

Hyperactive/Impulsive Symptoms (6/9 age <17 years; 5/9 ≥17 years)

- Interrupt or intrude on others
- Fidget with hands or feet or squirms in seat
- Have difficulty awaiting turn
- Leave seat in classroom inappropriately
- Are easily distracted
- Run about or climb excessively (or internal restlessness)
- Blurt out answers before questions are completed
- Have difficulty playing quietly
- Talk excessively
- Are “on the go” or acts as if “driven by a motor”

DSM-5 Criteria for ADHD: Inattentive Symptoms
(6/9 age <17 years; 5/9 ≥17 years)

- Fail to give close attention to details
- Are forgetful in daily activities
- Are easily distracted
- Lose things necessary for tasks
- Avoid tasks requiring sustained mental effort
- Have difficulty sustaining attention
- Do not seem to listen
- Do not follow through on instructions
- Have difficulty organizing tasks or activities

Twin Studies Show ADHD Is a Genetic Disorder

Average genetic contribution of ADHD based on twin studies

- Hudziak, 2000
- Nadder, 1998
- Levy, 1997
- Sherman, 1997
- Silberg, 1996
- Gjone, 1996
- Thapar, 1995
- Schmitz, 1995
- Edelbrock, 1992
- Gillis, 1992
- Goodman, 1989
- Willerman, 1973

Breast cancer:
- Hudziak, 2000
- Nadder, 1998
- Levy, 1997
- Sherman, 1997
- Silberg, 1996
- Gjone, 1996
- Thapar, 1995
- Schmitz, 1995
- Edelbrock, 1992
- Gillis, 1992
- Goodman, 1989
- Willerman, 1973

Asthma:
- Hudziak, 2000
- Nadder, 1998
- Levy, 1997
- Sherman, 1997
- Silberg, 1996
- Gjone, 1996
- Thapar, 1995
- Schmitz, 1995
- Edelbrock, 1992
- Gillis, 1992
- Goodman, 1989
- Willerman, 1973

Schizophrenia:
- Hudziak, 2000
- Nadder, 1998
- Levy, 1997
- Sherman, 1997
- Silberg, 1996
- Gjone, 1996
- Thapar, 1995
- Schmitz, 1995
- Edelbrock, 1992
- Gillis, 1992
- Goodman, 1989
- Willerman, 1973

Height:
- Hudziak, 2000
- Nadder, 1998
- Levy, 1997
- Sherman, 1997
- Silberg, 1996
- Gjone, 1996
- Thapar, 1995
- Schmitz, 1995
- Edelbrock, 1992
- Gillis, 1992
- Goodman, 1989
- Willerman, 1973

Issue of heritability vital in interview:

• If you are ADHD, each of your parents has a 30% odds of having suffering from it
• If your child is ADHD, you have a 50% probability of having silently suffered from it
Examining the Cognitive and Emotional Dysregulation Pathways in Adults with ADHD (Stressed vs Non-Stressed Situations)

Prefrontal Regulation during Alert, Non-Stress Conditions

DMPFC = dorsal medial prefrontal cortex; DLPFC = dorsal lateral prefrontal cortex; rIPFC = rostral lateral prefrontal cortex; VMPFC = ventral medial prefrontal cortex; NA = noradrenaline; DA = dopamine.

Delayed brain growth in ADHD (3 yrs.)


Ns: ADHD=223; Controls = 223
Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset

- Global and regional glucose metabolism by PET scan reduced in adults who have been hyperactive since childhood

- Largest reductions in:
  - Premotor cortex
  - Superior prefrontal cortex

Normal

With ADHD
ADHD is a developmental neurobehavioral disorder with biopsychosocial risk factors

- Maternal-fetal variables such as smoking, alcoholism, obstetrical complications, low birth weight
- Psychological variables such as abuse, deprivation, co-morbid mental health disorders
- Genetic loci: dopamine receptor polymorphisms, dopamine reuptake protein
- Strong neuroimaging correlates to all the above
Functional Impairment in Patients with ADHD Compared to Those Without

- Repeat a grade
- < high school
- Teen pregnancy
- STD
- Substance abuse
- Accident prone
- Serious car accident
- Arrested
- Incarcerated
- Fired from job

Subjects (%)

- ADHD
- Normal

References:
## Slide 4

### Common Comorbid Psychiatric Disturbances in Adolescents with ADHD

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Prevalence Among Adolescents with ADHD</th>
<th>Prevalence in General Adolescent Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic impairment</td>
<td>20–60%</td>
<td>5–15%</td>
</tr>
<tr>
<td>Major depressive disorder</td>
<td>9–32% (average 25%)</td>
<td>3–5%</td>
</tr>
<tr>
<td>Anxiety disorders</td>
<td>10–40% (average 25%)</td>
<td>3–10%</td>
</tr>
<tr>
<td>Conduct disorder</td>
<td>20–56%</td>
<td>Unknown</td>
</tr>
<tr>
<td>Oppositional defiant disorder</td>
<td>20–67% (average 35%)</td>
<td>2–16% (average 7–8%)</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>~6–10%</td>
<td>3–4%</td>
</tr>
</tbody>
</table>

ADHD = attention-deficit/hyperactivity disorder.
ADHD and Driving

Collisions (Self-Report)

DMV Reports

Driving Impairment

Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes

Zheng Chang, PhD, MSc; Patrick D. Quinn, PhD; Kwan Hur, PhD; Robert D. Gibbons, PhD; Arvid Sjolander, PhD; Henrik Larsson, PhD; Brian M. D’Onofrio, PhD
CONCLUSIONS AND RELEVANCE  Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity.
Adult ADHD and Car Accidents: What is Known about the Disorder’s Impact, and Its Treatment’s Impact on Outcomes

OBJECTIVES To estimate the association between ADHD and the risk of serious transport accidents and to explore the extent to which ADHD medication influences this risk among patients with ADHD.

DESIGN, SETTING, AND PARTICIPANTS In total, 17,408 patients with a diagnosis of ADHD were observed from January 1, 2006, through December 31, 2009, for serious transport accidents documented in Swedish national registers. The association between ADHD and accidents was estimated with Cox proportional hazards regression. To study the effect of ADHD medication, stratified Cox regression was used to the risk of accidents during the medication.

Relevant Points

- Males with ADHD had a 1.47 hazard ratio of serious car accidents
- Females had a hazard ratio of 1.45 of serious car accidents
- In males, taking medications for ADHD lead to a 58% risk reduction (in females it was statistically insignificant)

Attributable fractions suggested that 4% to 4.5% of the accidents in male patients with ADHD could have been avoided if they had been receiving treatment during the entire follow-up.

CONCLUSIONS AND RELEVANCE Attention-deficit/hyperactivity disorder is associated with an increased risk of serious transport accidents, and this risk seems to be possibly reduced by ADHD medication, at least among male patients. This should lead to increased awareness among clinicians and patients of the association between serious transport accidents and ADHD medication.

Impact of ADHD Pharmacotherapy on Later Substance Use Disorders

More likely to have SUD* | Less likely to have SUD*

- Barkley
- Molina
- Loney
- Huss
- Biederman
- Lambert

SUD = substance use disorder
*Compared to unmedicated youth with ADHD

OR = 1

Meta-analysis of alcohol studies
Meta-analysis of drug studies
A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment

Monica Shaw¹†, Paul Hodgkins²†, Hervé Caci³, Susan Young⁴, Jennifer Kahle⁵, Alisa G Woods⁶ and L Eugene Arnold⁷
Figure 6 Benefit and no benefit with treatment by outcome group. This graph shows benefit (dark green bars) or no benefit (light green bars) by outcome group in treated participants with attention deficit hyperactivity disorder (ADHD) versus untreated ADHD. Improvement was reported most often in studies of driving and obesity outcomes (left side), with a greater proportion of outcomes reported to exhibit no benefit following treatment compared with no treatment in studies of occupation (right side). An intermediate proportion of studies of self-esteem, social function, academic, drug use/addictive behavior, antisocial behavior, and services use outcomes reported benefit with treatment.
MiniReview

Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study

Mats Fredriksen and Dawn E. Peleikis

1Division of Mental Health and Addiction, Vestfold Hospital Trust, Tonsberg, Norway, 2University of Oslo, Oslo, Norway and 3Department of Psychiatry, Akershus University Hospital, Grorud Outpatient Clinic, Lorenskog, Norway

(Received 13 April 2015; Accepted 13 August 2015)
on 250 medication-naïve patients with ADHD referred to a specialized outpatient clinic. Comorbid psychiatric disorders were diagnosed among 75% of the patients. About 56% had not completed secondary school, and 51% had been unable to work the preceding year. Persisting inattentive symptoms and comorbid mental disorders in adulthood were related to long-term work disability. In the prospective observational study of the thesis, patients were treated with methylphenidate as first-line drug and atomoxetine or dexamphetamine as second-line drugs, according to current treatment guidelines. At 12-month follow-up, 232 patients completed evaluation and 70% persisted on medication. About 80% of these used methylphenidate. Sustained improvement of symptoms and functioning was related to continued medication. Comorbid mental disorders and side effects were related to lower effectiveness and adherence, and 12% stopped medication due to side effects. Summing up the MiniReview, treatment
Childhood Attention-Deficit/Hyperactivity Disorder and the Emergence of Personality Disorders in Adolescence: A Prospective Follow-Up Study

- Individuals diagnosed with childhood ADHD are at increased risk for personality disorders in late adolescence, specifically borderline (OR = 13.16), antisocial (OR = 3.03), avoidant (OR = 9.77), and narcissistic (OR = 8.69) personality disorders.

- Those with persistent ADHD were at higher risk for antisocial (OR = 5.26) and paranoid (OR = 8.47) personality disorders but not the other personality disorders when compared to those in whom ADHD remitted.
Adult Adhd: presentation, diagnosis, differential
DSM-V Revisions to ADHD

- Same criteria as DSM-IV
- Onset before age 12 (age 7 in DSM-IV)
- 5 symptom criteria in adults (6 in DSM-IV)
- Removed autism-spectrum d/o from excluders
- Elaborated ADHD criteria descriptions (more examples for adults)

2013 American Psychiatric Association. DSM-5
Unexpectedly, the childhood-ADHD and adult-ADHD groups comprised virtually non-overlapping sets; 90% of adult-ADHD cases lacked a history of childhood ADHD. Also unexpectedly, the adult-ADHD group did not show tested neuropsychological deficits in childhood or adulthood, nor did they show polygenic risk for childhood ADHD.

Conclusion—Findings raise the possibility that adults presenting with the ADHD symptom picture may not have a childhood-onset neurodevelopmental disorder. If this finding is replicated, then the disorder's place in the classification system must be reconsidered, and research must investigate the etiology of adult ADHD.
Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood
Evidence From a Birth Cohort Supporting a Late-onset Syndrome
CONCLUSIONS AND RELEVANCE  The findings of this study do not support the assumption that adulthood ADHD is necessarily a continuation of childhood ADHD. Rather, they suggest the existence of 2 syndromes that have distinct developmental trajectories.
Evaluation of the Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young Adulthood

Jessica C. Agnew-Blais, ScD; Guilherme V. Polanczyk, MD, PhD; Andrea Danese, MD, PhD; Jasmin Wertz, MSc; Terrie E. Moffitt, PhD; Louise Arseneault, PhD
CONCLUSIONS AND RELEVANCE  We identified heterogeneity in the DSM-5 young adult ADHD population such that this group consisted of a large, late-onset ADHD group with no childhood diagnosis, and a smaller group with persistent ADHD. The extent to which childhood-onset and late-onset adult ADHD may reflect different causes has implications for genetic studies and treatment of ADHD.
Age-dependent decline of ADHD Symptoms

Mean Number of Symptoms

Age (year)
<6 6–8 9–11 12–14 15–17 18–20
Syndromatic Criteria
Inattention
Impulsivity
Hyperactivity
Fonctional impairments

Inattention
Impulsivity
Hyperactivity
Syndromatic Criteria
Fonctional impairments
| TABLE 3. |
| Differential Diagnosis of Attention-Deficit/Hyperactivity Disorder |

**Psychiatric Disorders**
- Oppositional defiant disorder
- Disruptive mood dysregulation disorder
- Intermittent explosive disorder
- Bipolar disorder
- Autism spectrum disorder
  - Anxiety disorders
- Intellectual developmental disorder
  - Substance use disorders
  - Personality disorders

**Psychosocial Conditions**
- Abuse and/or neglect
- Poor nutrition
- Neighborhood violence
- Chaotic family situation
- Being bullied

**Medical Disorders**
- Medication-induced symptoms (eg, asthma medications)
- Sensory impairments (poor eyesight or hearing)
- Seizure disorder
- Thyroid abnormality
- Heavy metal poisoning
- Head trauma
  - Apnea or other sleep disorders
### ASRS Screener v1.1

#### 1. Inattention

<table>
<thead>
<tr>
<th>Question</th>
<th>Never</th>
<th>Rarely</th>
<th>Sometimes</th>
<th>Often</th>
<th>Very Often</th>
</tr>
</thead>
<tbody>
<tr>
<td>How often do you have trouble wrapping up the final details of a project, once the challenging parts have been done?</td>
<td>0</td>
<td>1</td>
<td>2*</td>
<td>3*</td>
<td>4*</td>
</tr>
<tr>
<td>How often do you have difficulty getting things in order when you have to do a task that requires organization?</td>
<td>0</td>
<td>1</td>
<td>2*</td>
<td>3*</td>
<td>4*</td>
</tr>
<tr>
<td>When you have a task that requires a lot of thought, how often do you avoid or delay getting started?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3*</td>
<td>4*</td>
</tr>
<tr>
<td>How often do you have problems remembering appointments or obligations?</td>
<td>0</td>
<td>1</td>
<td>2*</td>
<td>3*</td>
<td>4*</td>
</tr>
</tbody>
</table>

#### 1. HyperactivityImpulsivity

<table>
<thead>
<tr>
<th>Question</th>
<th>Never</th>
<th>Rarely</th>
<th>Sometimes</th>
<th>Often</th>
<th>Very Often</th>
</tr>
</thead>
<tbody>
<tr>
<td>How often do you fidget or squirm with your hands or feet when you have to sit down for a long time?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3*</td>
<td>4*</td>
</tr>
<tr>
<td>How often do you feel overly active and compelled to do things, like you were driven by a motor?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3*</td>
<td>4*</td>
</tr>
</tbody>
</table>

**Significant items in Red (*p=0.5); Likely to have ADHD with ≥ 4 significant items**

World Health Organization  
http://www.med.nyu.edu/psych/assets/adhdscreen18.pdf
Adult ASRS Screener and Question list

• Standardized and useful screening, diagnostic, and follow up tool
  – Use all the questions on the ASRS list, not just screener in interview

• Threshold for Likely to Have ADHD: ≥4 significant items on screener

• Screener Sensitivity = 68.7%

• Screener Specificity = 99.5%

• Positive predictive value (PPV) using 3% estimate of prevalence = 80%

• More follow up done on positive screener questions, higher the PPV

• Total ASRS designed and useful to track treatment response
Is he DISTRACTED? Considerations when diagnosing ADHD in an adult

Richard C. Christensen, MD, MA
Adult attention-deficit/hyperactivity disorder (ADHD) can be challenging to assess accurately. Adult ADHD differs significantly from childhood ADHD, in that hyperactivity often is absent or greatly diminished, comorbid disorders (depression or substance use) are common, and previously compensated attention deficits in school can manifest in the patient's personal and professional life.

The mnemonic DISTRACTED can help when recalling key components in assessing adult ADHD. Because ADHD is a developmental disorder—there are signs of onset in childhood—it is important to maintain a longitudinal view when asking about patterns of behavior or thinking.

**Distractibility.** Is there a pattern of getting "off track" in conversations or in school or work situations because of straying thoughts or daydreams? Is there a tendency to overrespond to extraneous stimuli (e.g., cell phones, computers, television) that impedes the patient's ability to converse, receive information, or follow directions?

**Impulsivity.** Does the patient have a history of saying things "off the cuff," interrupting others, or "walking on" someone else's words in a conversation? Is impulsivity evident in the person's substance use or spending patterns?

**School history.** This domain is important in diagnosing ADHD in adults because there needs to be evidence that the disorder was present from an early age. How did the patient perform in school (i.e., grades, organization, completion of homework assignments)? Was there a behavioral pattern that reflected hyperactivity (could not stay seated) or emotional dysregulation (frequent outbursts)?

**Task completion.** Does the patient have trouble finishing assignments at work, staying focused on a project that is considered boring, or completing a home project (e.g., fixing a leaky faucet) in a timely fashion?

**Rating scales.** Rating scales should be used to help support the diagnosis, based on the patient's history and life story. There are >12 scales that can be utilized in a clinical setting; the ADHD/Hyperactivity Disorder Self-Report Scale is a brief and easy measure of core ADHD symptoms.

**Accidents.** Adults with ADHD often are accident-prone because of inattention, hyperactivity, or impulsivity. Does the patient have a history of unintentionally hurting himself because he "wasn't paying attention" (falls, burns), or was too impatient (traffic accidents or citations)?

**Commitments.** Does the patient fail to fulfill verbal obligations (by arriving late, forgetting to run errands)? Has this difficulty to commit created problems in relationships over time?

**Time management.** How difficult is it for the patient to stay organized while balancing work expectations, social obligations, and family needs? Is there a pattern of chaotic scheduling with regard to meals, work, or sleeping?
Employment. Has the patient changed jobs because the work becomes “too boring” or “uninteresting”? Is there a pattern of being terminated because of poor work quality based on time management or job performance?

Decisions. Adults with ADHD often make hasty, ill-informed choices or procrastinate so that they do not have to make a decision. Does the patient’s decision-making reveal a pattern of being too distracted to hear the information needed, or too impatient to consider all the details?

Remember: No single component of this mnemonic alone suffices to make a diagnosis of adult ADHD. However, these considerations will help clarify what lies behind your DISTRACTED patient’s search for self-understanding and appropriate medical care.

References
The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5

Berk Ustun, MS; Lenard A. Adler, MD; Cynthia Rudin, PhD; Stephen V. Faraone, PhD; Thomas J. Spencer, MD; Patricia Berglund, MBA; Michael J. Gruber, MS; Ronald C. Kessler, PhD
Case Presentation: Diagnostic Prioritization for Pharmacotherapy

Order of treatment also considers the severity of the concurrent disorders.

Borderline Personality
Alcohol and substance abuse
Mood disorders
Bipolar and MDD
Anxiety disorders
  Obsessive-compulsive disorder,
  generalized anxiety disorder,
  panic
ADHD

McLean Screening Instrument for Borderline Personality Disorder

1. Have any of your closest relationships been troubled by a lot of arguments or repeated breakups? 1 = yes 0 = no
2. Have you deliberately hurt yourself physically (e.g., punched yourself, cut yourself, burned yourself)? How about made a suicide attempt? 1 = yes 0 = no
3. Have you had at least two other problems with impulsivity (e.g., eating binges and spending sprees, drinking too much and verbal outbursts)? 1 = yes 0 = no
4. Have you been extremely moody? 1 = yes 0 = no
5. Have you felt very angry a lot of the time? How about often acted in an angry or sarcastic manner? 1 = yes 0 = no
6. Have you often been distrustful of other people? 1 = yes 0 = no
7. Have you frequently felt unreal or as if things around you were unreal? 1 = yes 0 = no
8. Have you chronically felt empty? 1 = yes 0 = no
9. Have you often felt that you had no idea of who you are or that you have no identity? 1 = yes 0 = no
10. Have you made desperate efforts to avoid feeling abandoned or being abandoned (e.g., repeatedly called someone to reassure yourself that he or she still cared, begged them not to leave you, clung to them physically)? 1 = yes 0 = no
Moreover, ADHD and BPD frequently co-occur, with rates of BPD among adults with ADHD ranging from 19% to 37% (e.g., Miller et al.). Finally, there is evidence to suggest that childhood ADHD may be a risk factor.
Neuropsychological testing

• Not to be routinely done

• Possible indications:
  – To rule out school or workplace difficulties that appear unrelated to attentional deficits: learning disabilities, IQ issues
  – Question of organic or congenital brain lesions or neurological trauma donating to disability
  – To rule out psychiatric diagnoses that imitate or are comorbid to the cardinal ADHD symptoms but are difficult to identify
  – Lack of treatment response
  – Malingering or factitious disorders suspected
Diagnostic considerations: Summary

• While the ASRS cannot replace the diagnostic interview, it should be given to all higher risk clients outlined and used to follow treatment results

• The ASRS results should form a basis for further questioning, using the positive test items as a base (DISTRACTED)

• Corroboration by previous scholastic history, marks, childhood, and everyday behaviors by relatives/parents/spouse very helpful

• Comorbidity is the rule rather than the exception and mood/anxiety disorders common
Odds Ratio (95% CI). *P < .05.

GAD = generalized anxiety disorder; NCS-R = National Comorbidity Survey Replication; OCD = obsessive-compulsive disorder; PTSD = posttraumatic stress disorder.

### ADHD and SUD: Increased Risks across the Board

Population-based sample of Swedish adult twins (N = 18,167)

Associations of ADHD Symptoms with SUD (Adjusted for Sex, Age, and Education and Controlled for the Random Effect of Twins) Compared with Controls/Twins with No ADHD Symptoms

<table>
<thead>
<tr>
<th>Substance Abuse</th>
<th>All Twins, n (%)</th>
<th>ADHD OR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alcohol</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol abuse</td>
<td>543 / 17,940 (3.06)</td>
<td>1.88</td>
</tr>
<tr>
<td>Alcohol dependence</td>
<td>1270 / 17,731 (7.18)</td>
<td>3.50</td>
</tr>
<tr>
<td><strong>Drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opiate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabinoid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Illicit drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poly-substance use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poly-substance use including alcohol</td>
<td>1704 / 18,027 (9.42)</td>
<td>2.78</td>
</tr>
<tr>
<td><strong>Nicotine (smoke and/or “snus”)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular nicotine use</td>
<td>3115 / 18,167 (17.15)</td>
<td>1.33</td>
</tr>
</tbody>
</table>

ADHD Sxs and subtypes are associated with increased risks for all SUD outcomes; no difference between ADHD subtypes, no substance preference, and no sex differences for the comorbidity

*P ≤ .001. Calculated from multilevel logistic regression adjusted for sex, age, and education and controlled for the random effect of twins.*

Prevalence of SUD: Prospective 4-Year Follow-up Study

Overall Rate of Substance Use Disorder

<table>
<thead>
<tr>
<th>Group</th>
<th>Percentage of Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unmedicated ADHD (n=19)</td>
<td>75%</td>
</tr>
<tr>
<td>Medicated ADHD (n=56)</td>
<td>25%</td>
</tr>
<tr>
<td>Non-ADHD Control (n=137)</td>
<td>18%</td>
</tr>
</tbody>
</table>

P < .001 across groups.
In the largest study to examine whether ADHD medications are associated with differences in risk for substance-related problems, researchers identified 3 million individuals aged 13 years or older who received either an ADHD diagnosis or treatment for ADHD with a stimulant or non-stimulant atomoxetine from 2005 to 2014.

Models showed that use of ADHD medication was associated with 35% lower odds of concurrent substance-related events among men and 31% lower odds among women.
Dealing with comorbidity in treatment

SUD:

determine pattern and severity and potential risk of med interactions or medication diversion

Detox-rehab needed to clear sud-related symptoms

When some results achieved, use either atomoxetine or long acting stimulants, depending on relapse risk.

Mood disorders:

Treat the primary affective state with antidepressants or mood stabilizers;

If the core inattentive symptoms persist, add on extended release stimulants or atomoxetine;

Odds of manic switch appear rare with mood stabilizers in place
ADHD and Bipolarity: Controversial

Potentially huge rates of ADHD comorbidity have been found in children with Manic-Depressive disorder, but this is hotly disputed, and is an issue in adults as well.

22% of ADHD adults appear to suffer from bipolarity, men=women.

Treat the bipolarity first with mood stabilizers, consider all treatment options thereafter if ADHD symptoms remain and are disabling; little evidence that one treatment creates more switches into mania than any other if already stabilized.

Distinguishing the symptoms of mania from ADHD is a concern, features that help include:

Discrete but prolonged dysphoric or euphoric episodes
Psychotic symptoms such as delusions
Decreased need for sleep
Grandiosity, hypersexuality, bizzareness

ADHD has significant and chronic attention deficits.
Case Presentation: Diagnostic Prioritization for Pharmacotherapy

Borderline Personality
Alcohol and substance abuse
Mood disorders
Bipolar and MDD
Anxiety disorders
Obsessive-compulsive disorder, generalized anxiety disorder, panic
ADHD

Order of treatment also considers the severity of the concurrent disorders.

Effect sizes were heterogeneous for most outcome measures. Studies with active control groups showed smaller effect sizes. Neither participant medication status nor treatment format moderated pre-to-post treatment effects, and longer treatments were not associated with better outcomes.
Important practical issues in pharmacotherapy:

- Stimulant therapy is the backbone of short and long term improvement in all facets of the disorder and social development.
- Compliance can be terrible given the forgetfulness and disorganization (i.e., BID, TID dosings).
- Meds act quickly and effect fades quickly once blood levels drop: over minutes!
- This lack of 12-18 hour medication coverage has daily functional consequences.
- There can be a huge difference in perceived and measured side effects and effectiveness with different formulations, even of the same molecule.
- Tendency for abuse, tolerability, and medication interactions varies significantly with longer vs. shorter acting formulations.
- Non stimulants take weeks, not days to work.
The 24-Hour Day of a Typical Adult and Why the Adult with ADHD Needs Longer than 8- to 12-Hour Coverage of Symptoms / Day
ADHD Pharmacotherapy – Responsiveness

(remission rates: 15-20% less)

Effect size:

- Methylphenidate: 0.89
- Amphetamine: 0.7
- Atomoxetine
- Bupropion
- MAOI
- Clonidine
- Guanfacine

% Responders

Meta Analysis of Controlled Crossover Comparing Stimulants

7 Studies
174 subjects

1. Arnold L.E. J Att Disorders 2000
# CADDRA Guide to ADHD Pharmacological Treatments in Quebec - 2017

<table>
<thead>
<tr>
<th>Medications available and Illustrations</th>
<th>Characteristics</th>
<th>Duration of action</th>
<th>Starting dose</th>
<th>Dose titration as per product monograph</th>
<th>Dose titration as per CADDRA</th>
<th>RAMQ-coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMPHETAMINE-BASED PSYCHOSTIMULANTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexedrine® Tablets 5 mg</td>
<td>Pill can be crushed</td>
<td>~ 4 h</td>
<td>Tablets = 2.5 to 5 mg BID</td>
<td>↑ 2.5 - 5 mg at weekly intervals; Max. dose/day: (q.d. or b.i.d.) All ages = 40 mg</td>
<td>↑ 2.5 - 5 mg/day at weekly intervals</td>
<td>Covered</td>
</tr>
<tr>
<td>Dexedrine® spraysules 10, 15 mg</td>
<td>Sparanules (not crushable)</td>
<td>~ 6 - 8 h</td>
<td>Sparanules = 10 mg q.d. a.m.</td>
<td>Children: 5 mg at weekly intervals Max. dose/day: Children = 30 mg Adolescents and Adults = 60 - 30 mg</td>
<td>Adults = 50 mg</td>
<td>Covered</td>
</tr>
<tr>
<td>Adderall® XR Capsules 5, 10, 15, 20, 25, 50 mg</td>
<td>Sprinkable Granules</td>
<td>~ 12 h</td>
<td>5 - 10 mg q.d. a.m.</td>
<td>Children: 5 mg at weekly intervals Max. dose/day: Children = 30 mg Adolescents and Adults = 60 - 30 mg</td>
<td>Adults = 50 mg</td>
<td>Médicament d’exception program Child-Adolescent: (SN103) Adult: (SN32)</td>
</tr>
<tr>
<td>Vyvanse® Capsules 10, 20, 30, 40 50, 60 mg</td>
<td>Capsule content can be diluted in water, orange juice and yogurt</td>
<td>~ 13 - 14 h</td>
<td>20 - 30 mg q.d. a.m.</td>
<td>↑ by clinical discretion at weekly intervals Max. dose/day: All ages = 60 mg</td>
<td>↑ 10 mg at weekly intervals Max. dose/day: Children = 60 mg Adolescents and Adults = 70 mg</td>
<td>Médicament d’exception program Child-Adolescent: (SN103) Adult: (SN32)</td>
</tr>
</tbody>
</table>

| **METHYLPHENIDATE-BASED PSYCHOSTIMULANTS** |                 |                   |              |                                        |                            |                |
| Methylenidate short acting, tablets 5 mg (generic) 10, 20 mg (Ritalin®) | Pill can be crushed | ~ 3 - 4 h         | 5 mg b.i.d. to t.i.d. Adult = consider q.i.d. | ↑ 5 - 10 mg at weekly intervals Max. dose/day: All ages = 60 mg | ↑ 5 mg at weekly intervals Max. dose/day: Children and Adolescents = 60 mg Adults = 100 mg | Covered        |
| Biphen® Capsules 10, 15, 20, 30, 40, 50, 60, 80 mg | Sprinkable Granules | ~ 10 - 12 h        | 10 - 20 mg q.d. a.m. | ↑ 10 mg at weekly intervals Max. dose/day: Children and Adolescents = 60 mg Adults = 80 mg | ↑ 5 - 10 mg at weekly intervals Max. dose/day: Children = 60 mg Adolescents and Adults = 80 mg | Médicament d’exception program Child-Adolescent: (SN103) Adult: (SN32) |
| Concerta® Extended Release Tabs 18, 27, 36, 54 mg | Pill needs to be swallowed whole to keep delivery mechanism intact | ~ 12 h             | 16 mg q.d. a.m. | ↑ 18 mg at weekly intervals Max. dose/day: Children = 54 mg Adolescents = 90 mg / Adults = 122 mg | ↑ 9 - 18 mg at weekly intervals Max. dose/day: Children = 72 mg Adolescents = 90 mg / Adults = 108 mg | Médicament d’exception program Child-Adolescent: (SN103) Adult: (SN32) |

| **NON PSYCHOSTIMULANT – SELECTIVE NOREPIEPHINE RENUPTAKE INHIBITOR** |                 |                   |              |                                        |                            |                |
| Strattera® (Atomoxetine) Capsules 10, 18, 25, 40, 60, 80, 100 mg | Capsule needs to be swallowed whole to reduce off side effects | Up to 24 h         | Children and Adolescents: 0.5 mg/kg/day Adults = 40 mg q.d. for 7-14 days | Maintain dose for a minimum of 7 - 14 days before adjusting: Children = 0.8 then 1.2 mg/kg/day 70 kg or Adults = 60 then 80 mg/kg/day Max. dose/day: 1.4 mg/kg/day or 100 mg | Maintain dose for a minimum of 7 - 14 days before adjusting: Children = 0.8 then 1.2 mg/kg/day 70 kg or Adults = 60 then 80 mg/kg/day Max. dose/day: 1.4 mg/kg/day or 100 mg | Médicament d’exception program Child-Adolescent Patient d’exception program Adult |

| **NON PSYCHOSTIMULANT – SELECTIVE ALPHA-2A ADRENERGIC RECEPTOR AGONIST** |                 |                   |              |                                        |                            |                |
| Intuniv® (Guanfacine XR) Extended release tabs 1, 2, 3, 4 mg | Pill needs to be swallowed whole to keep delivery mechanism intact | Up to 24 h | 1 mg q.d. (morning or evening) | Maintain dose for a minimum of 7 days before adjusting by no more than 1 mg increment weekly Max. dose/day: Monotherapy: 6-12 years 4 mg 13-17 years: 7 mg Adjunctive therapy to psychostimulants 6-17 years: 4 mg | Maintain dose for a minimum of 7 days before adjusting by no more than 1 mg increment weekly Max. dose/day: Monotherapy: 6-12 years 4 mg 13-17 years: 7 mg Adjunctive therapy: 4 mg | Médicament d’exception program Child-Adolescent Patient d’exception program Adult |

*Note: Illustrations do not reflect real size of pills/capsules. For specific details on how to start, adjust and switch ADHD medications, clinicians are invited to refer to the Canadian ADHD Practice Guidelines (www.caddra.ca)*

*Pharmacological and psychosocial treatment were to be in the discretion of the physician and may be individually adjusted for each patient.*
Indications for Atomoxetine

Substance abusers: active or with high relapse risk

- Patients not responsive to stimulants
- Patients with significant side effects to stimulants (e.g., rebound, tics)
- Patients with Tourette’s Syndrome or chronic motor tic disorders
- Epilepsy
- Comorbid Anxiety
- Abuse or diversion is a concern

Bipolar disorder? Unstudied
**SLIDE 4**

Lisdexamfetamine – a prodrug that is therapeutically inactive until it is converted to active dextroamphetamine in the body.

Lisdexamfetamine (prodrug) → Rate-limited Hydrosis → l-lysine + d-amphetamine (active)

Site of cleavage
Results: Twenty-two of 2832 identified articles met inclusion criteria. The model-estimated effect size of LDX for European adults was 1.070 (95% confidence interval: 0.738, 1.401), larger than the 0.8 threshold for large effect sizes. The overall model fit was adequate (80%) and stable in the sensitivity analyses.

Conclusion: This model predicts that LDX may have a large treatment effect size in European adults with ADHD.

© 2015 Elsevier Masson SAS. All rights reserved.
Treatment (continued)

Canadian Resources

- CADDRA (www.caddra.ca)
- CADDAC (www.caddac.ca)
- Teach ADHD (www.teachadhd.ca)
- Learning Disabilities Assn of Canada (www.ldac-taac.ca)
- Learning Disabilities Assn of Ontario (www.ldao.ca)
- Association Québécoise des troubles d'apprentissage (www.aqeta.qc.ca)
- CH.A.D.D. Canada (www.chaddcanada.org)
- PANDA (www.associationpanda.qc.ca)
- The AD/HD Foundation (www.adhdfoundation.ca)